The spine company intends to use the proceeds to sustain global commercialization of its three minimally invasive products to treat degenerative disc disease with spinal fusion and vertebral compression fractures. It will also be used for additional initiatives to bring its fusion and VCF products to the U.S. market.
The three products include Benvenue Medical’s Kiva VCF Treatment System, Blazer Vertebral Augmentation System and Luna Interbody Spacer System.
More Articles on Orthopedic Devices:
Orthopedic Extremity Device Market to Surge Past $4.2B by 2016
Robert Wynalek Named Chief Operating and Commercialization Officer of Discgenics
NLT SPINE Reports Positive Clinical Results With PROW FUSION
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.